RecruitingNCT03971253

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Sponsor

Astellas Pharma Inc

Enrollment

3,000 participants

Start Date

Sep 2, 2019

Study Type

OBSERVATIONAL

Conditions

Rheumatoid Arthritis (RA)

Summary

The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a Japanese post-marketing surveillance study tracking the real-world safety and effectiveness of peficitinib — a JAK inhibitor — in patients with rheumatoid arthritis (RA). Rheumatoid arthritis is an autoimmune disease where the immune system mistakenly attacks the joints, causing pain, swelling, and stiffness. This study collects data on patients who are prescribed peficitinib for the first time outside of a clinical trial, helping regulators and doctors understand how well it works in everyday clinical practice. **You may be eligible if...** - You have rheumatoid arthritis - You are being prescribed peficitinib for the very first time - You are being treated in Japan **You may NOT be eligible if...** - You have previously taken peficitinib for any reason Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPeficitinib

Oral

Locations(47)

Site JP00023

Aichi, Japan

Site JP00005

Akita, Japan

Site JP00002

Aomori, Japan

Site JP00012

Chiba, Japan

Site JP00038

Ehime, Japan

Site JP00018

Fukui, Japan

Site JP00040

Fukuoka, Japan

Site JP00007

Fukushima, Japan

Site JP00021

Gifu, Japan

Site JP00010

Gunma, Japan

Site JP00034

Hiroshima, Japan

Site JP00001

Hokkaido, Japan

Site JP00028

Hyōgo, Japan

Site JP00008

Ibaraki, Japan

Site JP00017

Ishikawa, Japan

Site JP00037

Kagawa, Japan

Site JP00046

Kagoshima, Japan

Site JP00014

Kanagawa, Japan

Site JP00039

Kochi, Japan

Site JP00043

Kumamoto, Japan

Site JP00026

Kyoto, Japan

Site JP00024

Mie, Japan

Site JP00004

Miyagi, Japan

Site JP00045

Miyazaki, Japan

Site JP00020

Nagano, Japan

Site JP00042

Nagasaki, Japan

Site JP00029

Nara, Japan

Site JP00015

Niigata, Japan

Site JP00003

Numakunai, Japan

Site JP00033

Okayama, Japan

Site JP00047

Okinawa, Japan

Site JP00027

Osaka, Japan

Site JP00044

Ōita, Japan

Site JP00041

Saga, Japan

Site JP00011

Saitama, Japan

Site JP00025

Shiga, Japan

Site JP00032

Shimane, Japan

Site JP00022

Shizuoka, Japan

Site JP00009

Tochigi, Japan

Site JP00036

Tokushima, Japan

Site JP00013

Tokyo, Japan

Site JP00031

Tottori, Japan

Site JP00016

Toyama, Japan

Site JP00030

Wakayama, Japan

Site JP00006

Yamagata, Japan

Site JP00035

Yamaguchi, Japan

Site JP00019

Yamanashi, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03971253

Related Trials

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

NCT069331341 location

Oxidative Stress in Autoimmune Rheumatic Diseases

NCT075365291 location

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

NCT072588499 locations

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT0712303810 locations

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT070879122 locations